---
figid: PMC8231807__cancers-13-02968-g001
figtitle: 'FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in
  Clinical Practice'
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC8231807
filename: cancers-13-02968-g001.jpg
figlink: /pmc/articles/PMC8231807/figure/cancers-13-02968-f001/
number: F1
caption: '(A) Mechanism of action of FGFR inhibitors and FGFR signaling pathway: FGFR
  inhibitors act by inhibiting the FGFR downstream signaling pathway (B) Pathophysiology
  of FGFR-inhibitor-associated hyperphosphatemia: In kidneys, FGFR inhibitors target
  FGF23 ligand and FGFR1 receptor complex in the presence of klotho. Activation of
  the FGF23-FGFR1 pathway leads to inhibition of 25-OH vitamin D activation and degradation
  of 1, 25 (OH)2 vitamin D. FGFR inhibitors block the catabolism of 1, 25 (OH)2 vitamin
  D, and sodium-phosphate co-transporters in the proximal renal tubule cell thereby
  leading to hyperphosphatemia. (C) Pathophysiology of FGFR inhibitor-associated diarrhea:
  The FGFR4/FGF19/ERK1/2 pathway potentiates the conversion of cholesterol to bile
  acid in the liver. FGFR inhibitors block the conversion of cholesterol to bile acid
  thereby leading to altered bile acid metabolism.'
papertitle: 'FGFR Inhibitors in Oncology: Insight on the Management of Toxicities
  in Clinical Practice.'
reftext: Anuhya Kommalapati, et al. Cancers (Basel). 2021 Jun;13(12):2968.
year: '2021'
doi: 10.3390/cancers13122968
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: FGFR | hyperphosphatemia | urothelial carcinoma | cholangiocarcinoma | pemigatinib
  | erdafitinib
automl_pathway: 0.9550137
figid_alias: PMC8231807__F1
figtype: Figure
redirect_from: /figures/PMC8231807__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8231807__cancers-13-02968-g001.html
  '@type': Dataset
  description: '(A) Mechanism of action of FGFR inhibitors and FGFR signaling pathway:
    FGFR inhibitors act by inhibiting the FGFR downstream signaling pathway (B) Pathophysiology
    of FGFR-inhibitor-associated hyperphosphatemia: In kidneys, FGFR inhibitors target
    FGF23 ligand and FGFR1 receptor complex in the presence of klotho. Activation
    of the FGF23-FGFR1 pathway leads to inhibition of 25-OH vitamin D activation and
    degradation of 1, 25 (OH)2 vitamin D. FGFR inhibitors block the catabolism of
    1, 25 (OH)2 vitamin D, and sodium-phosphate co-transporters in the proximal renal
    tubule cell thereby leading to hyperphosphatemia. (C) Pathophysiology of FGFR
    inhibitor-associated diarrhea: The FGFR4/FGF19/ERK1/2 pathway potentiates the
    conversion of cholesterol to bile acid in the liver. FGFR inhibitors block the
    conversion of cholesterol to bile acid thereby leading to altered bile acid metabolism.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - kras
  - braf
  - si:dkey-222f8.3
  - mtor
  - fgfr1a
  - cyp24a1
  - fgfr4
  - fgf19
  - mapk3
  - KRAS
  - NRAS
  - BRAF
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - PIK3CG
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - CYP24A1
  - FGF19
---
